Nora K Horick

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4481206/publications.pdf

Version: 2024-02-01

103 papers

3,645 citations

304743 22 h-index 57 g-index

103 all docs

103
docs citations

103 times ranked 7611 citing authors

#	Article	IF	Citations
1	Neoadjuvant versus Postoperative Chemoradiotherapy is Associated with Improved Survival for Patients with Resectable Gastric and Gastroesophageal Cancer. Annals of Surgical Oncology, 2022, 29, 242-252.	1.5	4
2	Do you mind if I record?: Perceptions and practice regarding patient requests to record clinic visits in oncology. Cancer, 2022, 128, 275-283.	4.1	5
3	Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)., 2022, 10, e003847.		44
4	Effects of a perioperative geriatric intervention for older adults with Cancer: A randomized clinical trial. Journal of Geriatric Oncology, 2022, 13, 410-415.	1.0	19
5	Associations of sarcopenia with hematologic toxicity, treatment intensity, and healthcare utilization in patients with metastatic colorectal cancer Journal of Clinical Oncology, 2022, 40, 84-84.	1.6	1
6	Effect of a Symptom Monitoring Intervention for Patients Hospitalized With Advanced Cancer. JAMA Oncology, 2022, 8, 571.	7.1	13
7	Reply to: Endobronchial Optical Coherence Tomography: Shining New Light on Diagnosing UIP?. American Journal of Respiratory and Critical Care Medicine, 2022, , .	5.6	2
8	Abstract OT2-24-03: Phase II study of a PARP inhibitor in metastatic breast cancer with somatic <i>BRCA1/2</i> mutations identified by cell-free DNA: Genotyping based clinical trial. Cancer Research, 2022, 82, OT2-24-03-OT2-24-03.	0.9	0
9	Abstract P4-12-08: Accuracy of Patient Self-Reported Breast Cancer Disease Characteristics Compared to the Medical Record in a Trial of the Outcomes4MeDigital Health App. Cancer Research, 2022, 82, P4-12-08-P4-12-08.	0.9	О
10	Abstract PD5-11: Pilot study to assess prolonged nightly fasting in breast cancer survivors (LONGFAST). Cancer Research, 2022, 82, PD5-11-PD5-11.	0.9	0
11	Fractionated Proton Radiation Therapy and Hearing Preservation for Vestibular Schwannoma: Preliminary Analysis of a Prospective Phase 2 Clinical Trial. Neurosurgery, 2022, 90, 506-514.	1.1	6
12	Factors associated with psychological distress in caregivers of patients with malignant gliomas. Supportive Care in Cancer, 2022, 30, 5811-5820.	2.2	3
13	Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual patient data meta-analysis from randomized controlled trials. European Journal of Internal Medicine, 2022, 101, 41-48.	2.2	12
14	Pilot study to assess prolonged overnight fasting in breast cancer survivors (longfast). Breast Cancer Research and Treatment, 2022, , .	2.5	5
15	Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood, 2022, 139, 2306-2315.	1.4	62
16	A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma Journal of Clinical Oncology, 2022, 40, 8012-8012.	1.6	2
17	Changes in Functional Assessment of Cancer Therapy: General (FACT-G) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer Journal of Clinical Oncology, 2022, 40, 6570-6570.	1.6	0
18	Associations of baseline patientâ€reported outcomes with treatment outcomes in advanced gastrointestinal cancer. Cancer, 2021, 127, 619-627.	4.1	7

#	Article	IF	Citations
19	Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia. JAMA Oncology, 2021, 7, 238.	7.1	90
20	Abstract OT-30-02: Phase II study of talazoparib, a PARP inhibitor, in somaticBRCA1/2mutant metastatic breast cancer., 2021,,.		0
21	Posttraumatic stress disorder symptoms in patients with acute myeloid leukemia. Cancer, 2021, 127, 2500-2506.	4.1	14
22	Management and outcomes of men diagnosed with primary breast cancer. Breast Cancer Research and Treatment, 2021, 188, 561-569.	2.5	7
23	Palliative care for patients undergoing stem cell transplant: intervention components and supportive care measures. Bone Marrow Transplantation, 2021, 56, 1971-1977.	2.4	5
24	Survival outcomes, treatment toxicity, and healthcare utilization in older adults with aggressive non-Hodgkin lymphoma (NHL) Journal of Clinical Oncology, 2021, 39, 7557-7557.	1.6	0
25	Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss. Oncologist, 2021, 26, e963-e970.	3.7	9
26	Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer Journal of Clinical Oncology, 2021, 39, 6560-6560.	1.6	0
27	Phase II multicenter study of talazoparib for somatic <i>BRCA1/2</i> mutant metastatic breast cancer Journal of Clinical Oncology, 2021, 39, TPS1110-TPS1110.	1.6	2
28	Feasibility of integrating the Outcomes4Me smartphone navigation application into the care of breast cancer patients (FIONA) Journal of Clinical Oncology, 2021, 39, 1570-1570.	1.6	1
29	Clinical and mutational profile of ARID1A-mutated gastrointestinal cancers: Duration of response to platinum-based chemotherapy Journal of Clinical Oncology, 2021, 39, e15611-e15611.	1.6	1
30	Clinical Outcomes, Treatment Toxicity, and Health Care Utilization in Older Adults with Aggressive <scp>Non-Hodgkin</scp> Lymphoma. Oncologist, 2021, 26, 965-973.	3.7	5
31	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 499.	7.4	498
32	Diagnostic Accuracy of Endobronchial Optical Coherence Tomography for the Microscopic Diagnosis of Usual Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1164-1179.	5.6	32
33	Proton Radiation Therapy for Pediatric Craniopharyngioma. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1480-1487.	0.8	27
34	ASO Visual Abstract:ÂNeoadjuvant versusÂPostoperative Chemoradiotherapy Is Associated with Improved Survival in Patients with Resectable Gastric and Gastroesophageal Cancer. Annals of Surgical Oncology, 2021, 28, 690-691.	1.5	0
35	Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival in patients with metastatic gastrointestinal (GI) cancer Journal of Clinical Oncology, 2021, 39, 154-154.	1.6	0
36	Hybrid laryngotracheal reconstruction vs single and double stage: Indications and outcomes. International Journal of Pediatric Otorhinolaryngology, 2021, 151, 110948.	1.0	3

#	Article	IF	Citations
37	Phase 1 Study of CD37-Directed CAR T Cells in Patients with Relapsed or Refractory CD37+ Hematologic Malignancies. Blood, 2021, 138, 653-653.	1.4	5
38	Sexual Function, Quality of Life, and Mood After Radiation Therapy in Patients with Anal Cancer. Journal of Gastrointestinal Cancer, 2020, 51, 204-210.	1.3	20
39	Multimodal psychosocial intervention for family caregivers of patients undergoing hematopoietic stem cell transplantation: A randomized clinical trial. Cancer, 2020, 126, 1758-1765.	4.1	32
40	Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes. Annals of Surgical Oncology, 2020, 27, 1400-1406.	1.5	22
41	Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2020, 27, 1122-1129.	1.5	29
42	Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. New England Journal of Medicine, 2020, 383, 2333-2344.	27.0	1,102
43	Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. Annals of Surgical Oncology, 2020, 27, 5161-5172.	1.5	4
44	Chemoradiationâ€Related Lymphopenia and Its Association with Survival in Patients with Squamous Cell Carcinoma of the Anal Canal. Oncologist, 2020, 25, 1015-1022.	3.7	11
45	Perceptions of prognosis and goal of treatment in patients with malignant gliomas and their caregivers. Neuro-Oncology Practice, 2020, 7, 490-497.	1.6	16
46	Integrating Symptoms Into the Diagnostic Criteria for Breast Cancer–Related Lymphedema: Applying Results From a Prospective Surveillance Program. Physical Therapy, 2020, 100, 2186-2197.	2.4	13
47	Randomized trial of a hospice video educational tool for patients with advanced cancer and their caregivers. Cancer, 2020, 126, 3569-3578.	4.1	6
48	The Patient's Voice: Adherence, Symptoms, and Distress Related to Adjuvant Endocrine Therapy After Breast Cancer. International Journal of Behavioral Medicine, 2020, 27, 687-697.	1.7	19
49	Patient Preferences for Use of Archived Biospecimens from Oncology Trials When Adequacy of Informed Consent Is Unclear. Oncologist, 2020, 25, 78-86.	3.7	7
50	Moving forward on all fronts: impact, patterns, and barriers to exercise in cancer survivors and patients living with advanced disease. Supportive Care in Cancer, 2020, 28, 4979-4988.	2.2	14
51	The Impact of an Introductory Radiation Oncology Curriculum (IROC) for Radiation Oncology Trainees Across the United States and Canada. International Journal of Radiation Oncology Biology Physics, 2020, 107, 408-416.	0.8	13
52	Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clinical Cancer Research, 2020, 26, 1877-1885.	7.0	67
53	Multisite randomized trial of integrated palliative and oncology care for patients with acute myeloid leukemia (AML) Journal of Clinical Oncology, 2020, 38, 12000-12000.	1.6	9
54	Screening Tool Identifies Older Adults With Cancer at Risk for Poor Outcomes. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 305-313.	4.9	10

#	Article	IF	CITATIONS
55	The role of circulating tumor DNA (ctDNA), tumor markers (TMs), and patient-reported outcomes (PROs) in predicting treatment response in patients with metastatic gastrointestinal (GI) cancer Journal of Clinical Oncology, 2020, 38, 833-833.	1.6	O
56	Chemoradiation-related lymphopenia and its association with survival in patients with anal cancer Journal of Clinical Oncology, 2020, 38, 3-3.	1.6	0
57	Medical oncologists' perceptions of clinical trials for underrepresented populations Journal of Clinical Oncology, 2020, 38, e19062-e19062.	1.6	0
58	Phase II trial of a PARP inhibitor in somatic BRCA mutant metastatic breast cancer Journal of Clinical Oncology, 2020, 38, TPS1113-TPS1113.	1.6	3
59	Relationships among skeletal muscle, symptom burden, health care use, and survival in hospitalized patients with advanced cancer Journal of Clinical Oncology, 2020, 38, 7006-7006.	1.6	0
60	Randomized trial of a symptom monitoring intervention for hospitalized patients with advanced cancer (NCT03396510) Journal of Clinical Oncology, 2020, 38, 12014-12014.	1.6	0
61	Comparison of the clinical features, treatment patterns, and tumor mutations of patients with intrahepatic (ICC) and extrahepatic (ECC) cholangiocarcinoma Journal of Clinical Oncology, 2020, 38, 580-580.	1.6	0
62	Oncologist experiences regarding patient-recorded clinical encounters: Implications for the patient-doctor relationship Journal of Clinical Oncology, 2020, 38, 290-290.	1.6	0
63	Use of patient-reported outcomes (PROs) to predict treatment outcomes in patients with advanced cancer Journal of Clinical Oncology, 2020, 38, 186-186.	1.6	0
64	Post-Traumatic Stress Disorder (PTSD) Symptoms in Patients with Acute Myeloid Leukemia (AML). Blood, 2020, 136, 44-45.	1.4	1
65	Practice, Preferences, and Practical Tips From Primary Care Physicians to Improve the Care of Cancer Survivors. Journal of Oncology Practice, 2019, 15, e600-e606.	2.5	18
66	The Impact of Chest Wall Boost on Reconstruction Complications and Local Control in Patients Treated for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 155-164.	0.8	35
67	FOLFOX plus zivâ€aflibercept or placebo in firstâ€line metastatic esophagogastric adenocarcinoma: A doubleâ€blind, randomized, multicenter phase 2 trial. Cancer, 2019, 125, 2213-2221.	4.1	14
68	Are rare cancer survivors at elevated risk of subsequent new cancers?. BMC Cancer, 2019, 19, 166.	2.6	5
69	Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. Leukemia, 2019, 33, 2393-2402.	7.2	44
70	High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy. Oncologist, 2019, 24, e275-e283.	3.7	18
71	QOLP-17. FACTORS ASSOCIATED WITH PSYCHOLOGICAL DISTRESS IN CAREGIVERS OF PATIENTS WITH MALIGNANT GLIOMAS. Neuro-Oncology, 2019, 21, vi201-vi201.	1.2	0
72	Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score. Breast Cancer Research and Treatment, 2019, 173, 375-383.	2.5	1

#	Article	IF	Citations
73	Clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations Journal of Clinical Oncology, 2019, 37, 4084-4084.	1.6	5
74	The individualized Goals of Care Discussion Guide: A simple tool to empower patients with metastatic breast cancer Journal of Clinical Oncology, 2019, 37, 11622-11622.	1.6	0
75	Aggressiveness of care and overall survival in young metastatic colorectal cancer patients Journal of Clinical Oncology, 2019, 37, 3563-3563.	1.6	2
76	Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 550-558.	1.1	95
77	Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor–Positive Breast Cancer. Cancer Discovery, 2018, 8, 336-353.	9.4	32
78	Clinicopathologic Features of Non–Small-Cell Lung Cancer Harboring an ⟨i⟩NTRK⟨/i⟩ Gene Fusion. JCO Precision Oncology, 2018, 2018, 1-12.	3.0	112
79	Physical symptoms in long-term survivors of rare cancer. Journal of Cancer Survivorship, 2018, 12, 835-842.	2.9	11
80	Multicenter phase II trial of pembrolizumab (pembro) in previously-treated metastatic esophageal cancer Journal of Clinical Oncology, 2018, 36, e16072-e16072.	1.6	1
81	CACHEXIO: Evaluation of body composition changes and immunotherapy in patients with metastatic cancer Journal of Clinical Oncology, 2018, 36, 209-209.	1.6	2
82	FIT: Functional and imaging testing for patients with metastatic cancer Journal of Clinical Oncology, 2018, 36, 208-208.	1.6	5
83	Adherence to Recommended Risk Management among Unaffected Women with a <i>BRCA</i> Mutation. Journal of Genetic Counseling, 2017, 26, 79-92.	1.6	28
84	Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials. Clinical Cancer Research, 2017, 23, 3628-3637.	7.0	99
85	Impact of the elimination of cost sharing for mammographic breast cancer screening among rural US women: A natural experiment. Cancer, 2017, 123, 2506-2515.	4.1	7
86	Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529. Advances in Radiation Oncology, 2017, 2, 110-117.	1.2	45
87	Physical and psychological health in rare cancer survivors. Journal of Cancer Survivorship, 2017, 11, 158-165.	2.9	16
88	Patient-reported priorities for survivorship care and experience discussing available services Journal of Clinical Oncology, 2017, 35, 200-200.	1.6	0
89	Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinumâ€sensitive ovarian, fallopian tube, or primary peritoneal cancer. Cancer, 2016, 122, 3297-3306.	4.1	2
90	Impact of Ipsilateral Blood Draws, Injections, Blood Pressure Measurements, and Air Travel on the Risk of Lymphedema for Patients Treated for Breast Cancer. Journal of Clinical Oncology, 2016, 34, 691-698.	1.6	136

#	Article	IF	CITATIONS
91	Knowledge and Uptake of Genetic Counseling and Colonoscopic Screening Among Individuals at Increased Risk for Lynch Syndrome and their Endoscopists from the Family Health Promotion Project. American Journal of Gastroenterology, 2016, 111, 285-293.	0.4	24
92	Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. European Journal of Cancer, 2016, 56, 85-92.	2.8	4
93	Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Research, 2015, 17, 56.	5.0	30
94	Clinical Grade "SNaPshot―Genetic Mutation Profiling in Multiple Myeloma. EBioMedicine, 2015, 2, 71-73.	6.1	12
95	Radiation Therapy Risk Factors for Development of Lymphedema in Patients Treated With Regional Lymph Node Irradiation for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 91, 760-764.	0.8	34
96	Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. JAMA Oncology, 2015, 1, 943.	7.1	294
97	Early Mortality in Newly Diagnosed Multiple Myeloma in the Context of Novel Drugs. Blood, 2015, 126, 3315-3315.	1.4	2
98	Factors Associated With Fear of Lymphedema After Treatment for Breast Cancer. Oncology Nursing Forum, 2014, 41, 473-483.	1.2	20
99	The Impact of Radiation Therapy on the Risk of Lymphedema After Treatment for Breast Cancer: A Prospective Cohort Study. International Journal of Radiation Oncology Biology Physics, 2014, 88, 565-571.	0.8	203
100	Prognostic significance of indeterminate lung nodules in renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 355-361.	1.6	7
101	Late effects in rare cancer registrants Journal of Clinical Oncology, 2014, 32, e20577-e20577.	1.6	0
102	Clinical grade "SNaPshot" genetic mutation profiling in multiple myeloma Journal of Clinical Oncology, 2014, 32, e19571-e19571.	1.6	0
103	Prognostic significance of indeterminate lung nodules in renal cell carcinoma Journal of Clinical Oncology, 2013, 31, 377-377.	1.6	O